Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging
Authors:
Open Access
- 1 July 2016
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 29 (7) , 735-742
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Emerging landscape of oncogenic signatures across human cancersNature Genetics, 2013
- Signatures of mutational processes in human cancerNature, 2013
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular PathologyArchives of Pathology & Laboratory Medicine, 2013
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 MutationsClinical Cancer Research, 2012
- KRAS mutation status in primary nonsmall cell lung cancer and matched metastasesCancer, 2010
- Genomic and Mutational Profiling to Assess Clonal Relationships Between Multiple Non–Small Cell Lung CancersClinical Cancer Research, 2009
- EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node MetastasesClinical Cancer Research, 2009
- Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLCBritish Journal of Cancer, 2008
- Reproducibility of the diagnosis of small adenocarcinoma of the lung and usefulness of an educational program for the diagnostic criteriaPathology International, 2005